Work

Neoadjuvant dalpiciclib combined with letrozole and dual HER2 blockade in HR+/HER2+ breast cancer: First-stage results of the HELEN HER2 017 trial.

Year: 2026

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2026.44.16_suppl.1054

Authors: Jiujun Zhu, Zhenduo Lu, Junzhao Wu, Xuhui Guo, Jianghua Qiao, Chengzheng Wang, Chongjian Zhang, Jiao Zhang, Dechuang Jiao, Juntao Li, Tian Xie, Lina Wang, Jiabin Wang, Yadong Sun, Yajie Zhao, Zhenzhen Liu

Institutions: Zhengzhou University, Henan Cancer Hospital

Language: English

Topic: Advanced Breast Cancer Therapies

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7162544813

Cites:

Cited by:

Related to: